Resource Use in the Last Year of Life among Patients Who Died with Versus of Prostate Cancer

Michaela A. Dinan, Yanhong Li, Yinghong Zhang, Suzanne B. Stewart, Lesley H. Curtis, Daniel J. George, Shelby D. Reed

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Prostate cancer poses a significant financial burden in the United States. However, most men with prostate cancer will die from noncancer causes. Concerns about increased resource utilization at the end of life have not been appropriately examined in this context. Materials and Methods We conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men who were diagnosed with and died of, as opposed to with, prostate cancer between 2000 and 2007. Within these 2 populations, we compared changes in the use of medical interventions, hospice, and overall health care costs to Medicare in the last year of life. Results Among 34,727 patients, those who died of prostate cancer had lower costs ($43,572 vs. $45,830; P <.001), largely because of lower mean inpatient costs ($20,769 vs. $29,851) and fewer hospitalizations (1.8 vs. 2.1), inpatient days (12.2 vs. 15.7), intensive care unit (ICU) days (1.4 vs. 3.4), and skilled nursing facility days (11.7 vs. 14.7; P <.001 for all). Outpatient and hospice costs were significantly greater among patients who died of prostate cancer, as was use of chemotherapy and androgen deprivation therapy. Patients who died of prostate cancer had approximately 12% lower costs than patients who died from other causes in adjusted analyses (fold-change, 0.88; 95% confidence interval [CI], 0.85-0.92). The single strongest predictor of increased costs at the end of life was receipt of multiple invasive procedures (fold increase in costs, 2.39; 95% CI, 2.22-2.58). Conclusion Patients who died of prostate cancer rather than from other causes had more hospice and outpatient use, less inpatient and ICU use, and lower overall costs. Efforts to shift care toward outpatient settings might provide more efficient and judicious care for patients during the end of life.

Original languageEnglish (US)
Pages (from-to)28-37.e2
JournalClinical Genitourinary Cancer
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Prostatic Neoplasms
Costs and Cost Analysis
Hospices
Inpatients
Medicare
Intensive Care Units
Outpatients
Confidence Intervals
Skilled Nursing Facilities
Ambulatory Care
Health Care Costs
Androgens
Patient Care
Epidemiology
Hospitalization
Drug Therapy
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Dinan, Michaela A. ; Li, Yanhong ; Zhang, Yinghong ; Stewart, Suzanne B. ; Curtis, Lesley H. ; George, Daniel J. ; Reed, Shelby D. / Resource Use in the Last Year of Life among Patients Who Died with Versus of Prostate Cancer. In: Clinical Genitourinary Cancer. 2016 ; Vol. 14, No. 1. pp. 28-37.e2.
@article{d05b5c7659704c68b8196a8ebd901bd5,
title = "Resource Use in the Last Year of Life among Patients Who Died with Versus of Prostate Cancer",
abstract = "Background Prostate cancer poses a significant financial burden in the United States. However, most men with prostate cancer will die from noncancer causes. Concerns about increased resource utilization at the end of life have not been appropriately examined in this context. Materials and Methods We conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men who were diagnosed with and died of, as opposed to with, prostate cancer between 2000 and 2007. Within these 2 populations, we compared changes in the use of medical interventions, hospice, and overall health care costs to Medicare in the last year of life. Results Among 34,727 patients, those who died of prostate cancer had lower costs ($43,572 vs. $45,830; P <.001), largely because of lower mean inpatient costs ($20,769 vs. $29,851) and fewer hospitalizations (1.8 vs. 2.1), inpatient days (12.2 vs. 15.7), intensive care unit (ICU) days (1.4 vs. 3.4), and skilled nursing facility days (11.7 vs. 14.7; P <.001 for all). Outpatient and hospice costs were significantly greater among patients who died of prostate cancer, as was use of chemotherapy and androgen deprivation therapy. Patients who died of prostate cancer had approximately 12{\%} lower costs than patients who died from other causes in adjusted analyses (fold-change, 0.88; 95{\%} confidence interval [CI], 0.85-0.92). The single strongest predictor of increased costs at the end of life was receipt of multiple invasive procedures (fold increase in costs, 2.39; 95{\%} CI, 2.22-2.58). Conclusion Patients who died of prostate cancer rather than from other causes had more hospice and outpatient use, less inpatient and ICU use, and lower overall costs. Efforts to shift care toward outpatient settings might provide more efficient and judicious care for patients during the end of life.",
author = "Dinan, {Michaela A.} and Yanhong Li and Yinghong Zhang and Stewart, {Suzanne B.} and Curtis, {Lesley H.} and George, {Daniel J.} and Reed, {Shelby D.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.clgc.2015.07.006",
language = "English (US)",
volume = "14",
pages = "28--37.e2",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "1",

}

Resource Use in the Last Year of Life among Patients Who Died with Versus of Prostate Cancer. / Dinan, Michaela A.; Li, Yanhong; Zhang, Yinghong; Stewart, Suzanne B.; Curtis, Lesley H.; George, Daniel J.; Reed, Shelby D.

In: Clinical Genitourinary Cancer, Vol. 14, No. 1, 01.02.2016, p. 28-37.e2.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Resource Use in the Last Year of Life among Patients Who Died with Versus of Prostate Cancer

AU - Dinan, Michaela A.

AU - Li, Yanhong

AU - Zhang, Yinghong

AU - Stewart, Suzanne B.

AU - Curtis, Lesley H.

AU - George, Daniel J.

AU - Reed, Shelby D.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Background Prostate cancer poses a significant financial burden in the United States. However, most men with prostate cancer will die from noncancer causes. Concerns about increased resource utilization at the end of life have not been appropriately examined in this context. Materials and Methods We conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men who were diagnosed with and died of, as opposed to with, prostate cancer between 2000 and 2007. Within these 2 populations, we compared changes in the use of medical interventions, hospice, and overall health care costs to Medicare in the last year of life. Results Among 34,727 patients, those who died of prostate cancer had lower costs ($43,572 vs. $45,830; P <.001), largely because of lower mean inpatient costs ($20,769 vs. $29,851) and fewer hospitalizations (1.8 vs. 2.1), inpatient days (12.2 vs. 15.7), intensive care unit (ICU) days (1.4 vs. 3.4), and skilled nursing facility days (11.7 vs. 14.7; P <.001 for all). Outpatient and hospice costs were significantly greater among patients who died of prostate cancer, as was use of chemotherapy and androgen deprivation therapy. Patients who died of prostate cancer had approximately 12% lower costs than patients who died from other causes in adjusted analyses (fold-change, 0.88; 95% confidence interval [CI], 0.85-0.92). The single strongest predictor of increased costs at the end of life was receipt of multiple invasive procedures (fold increase in costs, 2.39; 95% CI, 2.22-2.58). Conclusion Patients who died of prostate cancer rather than from other causes had more hospice and outpatient use, less inpatient and ICU use, and lower overall costs. Efforts to shift care toward outpatient settings might provide more efficient and judicious care for patients during the end of life.

AB - Background Prostate cancer poses a significant financial burden in the United States. However, most men with prostate cancer will die from noncancer causes. Concerns about increased resource utilization at the end of life have not been appropriately examined in this context. Materials and Methods We conducted a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data of men who were diagnosed with and died of, as opposed to with, prostate cancer between 2000 and 2007. Within these 2 populations, we compared changes in the use of medical interventions, hospice, and overall health care costs to Medicare in the last year of life. Results Among 34,727 patients, those who died of prostate cancer had lower costs ($43,572 vs. $45,830; P <.001), largely because of lower mean inpatient costs ($20,769 vs. $29,851) and fewer hospitalizations (1.8 vs. 2.1), inpatient days (12.2 vs. 15.7), intensive care unit (ICU) days (1.4 vs. 3.4), and skilled nursing facility days (11.7 vs. 14.7; P <.001 for all). Outpatient and hospice costs were significantly greater among patients who died of prostate cancer, as was use of chemotherapy and androgen deprivation therapy. Patients who died of prostate cancer had approximately 12% lower costs than patients who died from other causes in adjusted analyses (fold-change, 0.88; 95% confidence interval [CI], 0.85-0.92). The single strongest predictor of increased costs at the end of life was receipt of multiple invasive procedures (fold increase in costs, 2.39; 95% CI, 2.22-2.58). Conclusion Patients who died of prostate cancer rather than from other causes had more hospice and outpatient use, less inpatient and ICU use, and lower overall costs. Efforts to shift care toward outpatient settings might provide more efficient and judicious care for patients during the end of life.

UR - http://www.scopus.com/inward/record.url?scp=84952874886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952874886&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2015.07.006

DO - 10.1016/j.clgc.2015.07.006

M3 - Article

C2 - 26382223

AN - SCOPUS:84952874886

VL - 14

SP - 28-37.e2

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 1

ER -